Core Viewpoint - Kewaunee Scientific Corporation's shares have declined significantly following mixed financial results for the third quarter of fiscal 2026, indicating a negative market reaction to the company's performance [1][2]. Financial Performance - Net sales for the fiscal third quarter increased by 3.3% year over year to $69.4 million, up from $67.2 million, reflecting modest growth [2]. - Net earnings attributable to the company fell approximately 49% to $0.7 million from $1.35 million in the prior-year period, with diluted earnings per share dropping to 23 cents from 45 cents [2]. - Pre-tax earnings rose by 25.8% to $1.6 million, but the decline in net income was attributed to higher taxes and non-controlling interests [2]. Segment Performance - The domestic segment, the largest contributor, reported sales of $51 million, down 2% year over year, with net earnings declining to $2.29 million from $2.88 million [3]. - The international segment experienced strong growth, with sales increasing by 21.4% to $18.4 million and net earnings rising to $1.26 million from $0.48 million [4]. - Order backlog decreased to $183.2 million from $221.6 million a year earlier, indicating softening demand visibility [4]. Management Commentary - Management noted that the third quarter is typically the weakest due to seasonal effects, compounded by geopolitical and economic uncertainties [5]. - Despite challenges, management highlighted year-over-year sales growth and the resilience of the diversified portfolio, aided by the addition of Nu Aire's products [6]. Financial Position - Cash and cash equivalents decreased to $10.3 million from $17.2 million at the beginning of the fiscal year, reflecting ongoing investments [7]. - Long-term debt significantly declined to $42.3 million from $60.7 million, improving the debt-to-equity ratio to 0.68 from 0.99 [8]. Strategic Outlook - Strategic priorities include disciplined capital allocation, reinvestment in operations, and pursuing complementary acquisitions to expand product offerings and geographic reach [9]. - The company aims to accelerate debt reduction following the Nu Aire acquisition while maintaining flexibility for shareholder returns [10]. Other Developments - The acquisition of Nu Aire, completed in November 2024, continues to influence financial performance, including integration-related costs [11]. - Management expects Nu Aire to contribute meaningfully to growth and EBITDA over time, particularly in containment and airflow solutions [12].

Sales Performance - Sales for the quarter were $69,399,000, an increase of 3.2% from $67,167,000 in the comparable period of the prior year [90]. - Domestic sales for the quarter were $50,953,000, down 2.0% from $51,976,000 in the comparable period of the prior year, while international sales increased by 21.4% to $18,446,000 from $15,191,000 [90]. - For the nine months ended January 31, 2026, sales were $210,599,000, up 28.9% from $163,324,000 in the comparable period of the prior year, driven by a 29.6% increase in domestic sales [91]. Financial Metrics - Gross profit margin for the three months ended January 31, 2026 was 26.7%, compared to 27.4% in the prior year, while the nine-month margin improved to 28.1% from 27.4% [93]. - Operating expenses for the three months ended January 31, 2026 were $15,963,000, or 23.0% of sales, down from 24.0% in the prior year [95]. - Net earnings for the three months ended January 31, 2026 were $692,000, or $0.23 per diluted share, compared to $1,354,000, or $0.45 per diluted share, in the prior year [99]. - The Company had working capital of $54,793,000 at January 31, 2026, down from $64,651,000 at April 30, 2025, with a current ratio of 2.1-to-1.0 [101]. Order Backlog - The Company's order backlog was $183.2 million at January 31, 2026, down from $221.6 million at January 31, 2025 [92]. Strategic Acquisition - The acquisition of Nu Aire for $55.0 million enhances the Company's capabilities and market presence, particularly in laboratory furnishings [86][88]. Market Outlook - The Company anticipates continued volatility in project delivery and demand, influenced by external economic factors and construction schedules [103].

Financial Performance - Sales for the third quarter of fiscal year 2026 were $69,399,000, a 3.3% increase from $67,167,000 in the prior year quarter[3] - Pre-tax earnings increased by 25.8% to $1,604,000 compared to $1,275,000 in the prior year quarter[3] - Net earnings decreased to $692,000 from $1,354,000 in the prior year quarter[3] - Net sales for the three months ended January 31, 2026, were $69.399 million, an increase from $67.167 million in the same period of 2025, representing a growth of approximately 3.1%[20] - Operating profit for the three months ended January 31, 2026, was $2.582 million, up from $2.250 million in the prior year, indicating a growth of about 14.7%[20] - Net earnings attributable to Kewaunee Scientific Corporation for the three months ended January 31, 2026, were $692,000, a decrease from $1.354 million in the same period of 2025, representing a decline of approximately 48.9%[20] Sales Breakdown - Domestic sales decreased by 2.0% to $50,953,000, while international sales increased by 21.4% to $18,446,000[4][5] Assets and Liabilities - Total assets as of January 31, 2026, were $175.961 million, down from $194.654 million as of April 30, 2025, indicating a decrease of about 9.5%[22] - Total liabilities decreased to $103.433 million as of January 31, 2026, from $128.409 million as of April 30, 2025, reflecting a reduction of approximately 19.5%[22] Cash and Debt - Total cash on hand decreased to $10,347,000 from $17,164,000 on April 30, 2025[8] - Cash and cash equivalents decreased to $8.153 million as of January 31, 2026, from $14.942 million as of April 30, 2025, a decline of about 45.5%[22] - Short-term debt increased to $7,351,000 from $4,773,000 on April 30, 2025, while long-term debt decreased to $42,316,000 from $60,730,000[9] - The debt-to-equity ratio improved to 0.68-to-1 from 0.99-to-1 on April 30, 2025[9] Acquisition and Integration - The company completed the acquisition of Nu Aire and is focusing on integrating it to enhance growth and EBITDA contribution[10] - The company has integrated its newly acquired subsidiary, Nu Aire, which is expected to enhance its product offerings in laboratory equipment[16] - The third quarter results were impacted by seasonal factors and geopolitical uncertainties, but the addition of Nu Aire's products helped offset some softness in construction-related business[10] - The company anticipates potential risks related to the integration of Nu Aire and other operational uncertainties that could impact future performance[18] Operating Expenses - Kewaunee Scientific's operating expenses for the nine months ended January 31, 2026, were $47.696 million, compared to $35.560 million for the same period in 2025, an increase of approximately 34.1%[20] Order Backlog - The company's order backlog was $183.2 million as of January 31, 2026, down from $221.6 million a year earlier[3]

Core Insights - Kewaunee Scientific Corporation reported a 3.3% increase in sales for the third quarter of fiscal year 2026, totaling $69.4 million compared to $67.2 million in the same quarter of the previous year [1][2] - The company experienced a 25.8% increase in pre-tax earnings, reaching $1.6 million, while net earnings decreased to $692,000 from $1.4 million in the prior year [1][2] - The order backlog as of January 31, 2026, was $183.2 million, down from $221.6 million a year earlier [1] Financial Performance - Domestic sales decreased by 2.0% to $50.9 million, with net earnings from the domestic segment falling to $2.3 million from $2.9 million [1][2] - International sales increased by 21.4% to $18.4 million, with net earnings rising to $1.3 million from $476,000 in the prior year [1][2] - Corporate segment reported a pre-tax net loss of $3.1 million, slightly higher than the previous year's loss of $3.0 million [1][2] Cash and Debt Position - Total cash on hand decreased to $10.3 million from $17.2 million as of April 30, 2025 [1] - Short-term debt increased to $7.4 million from $4.8 million, while long-term debt decreased to $42.3 million from $60.7 million [1] - The debt-to-equity ratio improved to 0.68-to-1 from 0.99-to-1, indicating a stronger balance sheet [1] Strategic Initiatives - The company is focusing on integrating its newly acquired subsidiary, Nu Aire, to enhance growth and EBITDA contributions [1][2] - Investments are being made in corporate infrastructure to support future growth, including strengthening the corporate team and improving financial systems [1][2] - The CEO highlighted the importance of diversification and the resilience of the laboratory products portfolio amid challenging market conditions [1][2]

Core Insights - Kewaunee Scientific Corporation will attend the analytica 2026 tradeshow in Munich from March 24-27, showcasing its laboratory infrastructure and safety solutions alongside its subsidiary Nu Aire, Inc. [1] - The analytica trade fair is a significant global event for laboratory technology, expected to attract over 30,000 professionals and industry leaders [1] - Kewaunee and NuAire aim to demonstrate their integrated solutions and commitment to laboratory environments throughout their project lifecycle [1] Company Overview - Kewaunee Scientific Corporation, founded in 1906, specializes in the design, manufacture, and installation of laboratory and healthcare furniture products [1] - The company operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India, serving both domestic and international markets [1] - Nu Aire, Inc., acquired by Kewaunee, is a manufacturer of biological safety cabinets and other laboratory products, founded in 1971 [1] Event Participation - Kewaunee and NuAire will be located at Booth B1.110 during the analytica 2026 event, where they will present their laboratory solutions [1] - The collaboration with ibs tecnomara will enhance their offerings by providing local expertise to European lab planners and end users [1] - The showcased products will include Class II biosafety cabinets, controlled environment systems, adaptable bench systems, and energy-efficient fume hoods [1]

Core Viewpoint - Kewaunee Scientific Corporation plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after trading hours [1] Company Overview - Kewaunee Scientific Corporation, founded in 1906, is a global leader in designing, manufacturing, and installing laboratory, healthcare, and technical furniture products [1] - The company offers a range of products including steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks [1] - Corporate headquarters are located in Statesville, North Carolina, with sales offices in the United States, India, Saudi Arabia, and Singapore [1] - Kewaunee operates three manufacturing facilities in Statesville and one in Bangalore, India, serving both domestic and international markets [1] Recent Acquisition - Kewaunee Scientific's newly acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products [1] - Nu Aire was founded in 1971 and has its headquarters and manufacturing facilities in Plymouth, Minnesota, with additional capabilities in Long Lake, Minnesota, and a warehouse partnership in the Netherlands [1]

Core Viewpoint - Kewaunee Scientific Corporation experienced a decline in share price despite significant revenue growth, indicating potential challenges in profitability and operational efficiency [1][2][10]. Earnings & Revenue Performances - For the quarter ended October 31, 2025, Kewaunee reported net sales of $70.1 million, a 46.8% increase from $47.8 million in the same period last year [2]. - Net earnings attributable to Kewaunee decreased to $2.4 million from $3 million year-over-year, with diluted earnings per share falling to 82 cents from $1.01 [2]. Profitability Metrics - Pre-tax earnings declined 12.2% year-over-year to $3.5 million, while EBITDA increased to $5.8 million from $4.9 million, reflecting improved operating scale despite margin pressures [3][10]. Key Business Metrics - Order backlog was $192.9 million as of October 31, 2025, up from $184.4 million a year earlier but down from $214.6 million at the end of fiscal 2025 [4]. - Total cash on hand decreased to $13.7 million from $17.2 million at April 30, 2025, while working capital improved to $67.8 million from $60 million year-over-year [4]. Debt and Balance Sheet - Long-term debt decreased to $58.2 million from $60.7 million, and the debt-to-equity ratio improved to 0.88-to-1 from 0.99-to-1, indicating a strengthening balance sheet [5]. Segment Performance - Domestic sales increased 51.7% year-over-year to $55.2 million, driven by the acquisition of Nu Aire, Inc., although net earnings in the domestic segment fell to $3.6 million from $4.5 million due to lower manufacturing volumes [6]. - International sales rose 31% year-over-year to $14.9 million, with net earnings improving to $0.6 million from $0.4 million [6]. Management Commentary - Management noted volatility in project delivery timing but emphasized strong quoting and booking activity, which supports a robust backlog [7][11]. - The performance of Nu Aire was highlighted as a key factor offsetting weaknesses in the legacy construction-driven business [8]. Factors Influencing Results - Revenue growth was attributed to higher sales volumes in both Domestic and International segments, with the Nu Aire acquisition contributing significantly [9]. - Profitability pressures stemmed from lower manufacturing volumes in the Domestic business and increased operating expenses related to integration and corporate investments [10]. Future Outlook - Management expects continued volatility in project delivery timing but remains confident in strong backlog levels and sustained demand into fiscal 2027 [11]. - Early repayment of seller notes was noted as a positive development for the balance sheet and potential future acquisitions [11]. Other Developments - The quarter reflected ongoing integration of Nu Aire, with related fees impacting results but at lower levels than the previous year [12].

Sales Performance - Sales for the quarter were $70,096,000, an increase of 46.8% from $47,764,000 in the comparable period of the prior year[94] - Domestic sales for the quarter were $55,224,000, up 51.7% compared to $36,409,000 in the prior year[94] - International sales for the quarter were $14,872,000, up 31.0% from $11,355,000 in the comparable period of the prior year[94] Financial Metrics - Gross profit margin for the three months ended October 31, 2025 was 28.1%, down from 29.2% in the comparable quarter of the prior year[97] - Operating expenses for the three months ended October 31, 2025 were $15,613,000, or 22.3% of sales, compared to $9,518,000, or 19.9% of sales in the prior year[98] - Net earnings for the three months ended October 31, 2025 was $2,445,000, or $0.82 per diluted share, compared to $3,008,000, or $1.01 per diluted share in the prior year[103] - The effective income tax rate for the three months ended October 31, 2025 was 26.5%, compared to 23.3% for the same period in the prior year[100] Order Backlog and Working Capital - The Company's order backlog was $192.9 million at October 31, 2025, compared to $184.4 million at October 31, 2024[96] - The Company had working capital of $67,830,000 at October 31, 2025, compared to $64,651,000 at April 30, 2025[105] Growth Strategy - The Company remains focused on growth, both organically and inorganically, and is committed to making strategic investments to support this growth[109]

Financial Performance - Sales for the second quarter of fiscal year 2026 were $70,096,000, a 46.8% increase from $47,764,000 in the prior year quarter[3] - Pre-tax earnings decreased by 12.2% to $3,453,000 compared to $3,931,000 in the prior year quarter[3] - Kewaunee Scientific reported net sales of $70,096,000 for the three months ended October 31, 2025, a 46.7% increase from $47,764,000 in the same period of 2024[20] - Gross profit for the three months ended October 31, 2025, was $19,720,000, representing a 41.5% increase compared to $13,952,000 in the prior year[20] - Operating profit decreased slightly to $4,107,000 for the three months ended October 31, 2025, down from $4,434,000 in the same period of 2024[20] - Net earnings attributable to Kewaunee Scientific Corporation for the three months ended October 31, 2025, were $2,445,000, a decrease of 18.7% from $3,008,000 in the prior year[20] Sales Breakdown - Domestic sales increased by 51.7% to $55,224,000 from $36,409,000 in the prior year quarter[4] - International sales rose by 31.0% to $14,872,000 from $11,355,000 in the prior year quarter[5] Assets and Liabilities - The company’s total assets as of October 31, 2025, were $189,075,000, down from $194,654,000 as of April 30, 2025[22] - Total liabilities decreased to $117,358,000 as of October 31, 2025, compared to $128,409,000 as of April 30, 2025[22] - Kewaunee Scientific's cash and cash equivalents were $12,594,000 as of October 31, 2025, down from $14,942,000[22] - Total cash on hand was $13,679,000, down from $17,164,000 on April 30, 2025[8] - Long-term debt decreased to $58,164,000 from $60,730,000 on April 30, 2025[9] - The debt-to-equity ratio improved to 0.88-to-1 from 0.99-to-1 on April 30, 2025[9] Acquisition and Strategy - The acquisition of Nu Aire, Inc. is part of the company's strategy to diversify and enhance its laboratory solutions offerings[10] - The company has integrated its newly acquired subsidiary, Nu Aire, which is expected to enhance its product offerings in laboratory equipment[16] - Kewaunee Scientific anticipates that the acquisition of Nu Aire will provide significant benefits, although it faces risks related to competitive conditions and supply chain disruptions[18] Inventory and Backlog - The company's order backlog was $192.9 million as of October 31, 2025, compared to $184.4 million a year earlier[3] - The company reported an increase in inventories to $35,499,000 as of October 31, 2025, compared to $32,849,000 as of April 30, 2025[22] - The company expects strong demand for its products and a robust backlog through the end of the fiscal year[10]

Core Insights - Kewaunee Scientific Corporation reported a significant increase in sales for the second quarter of fiscal year 2026, with total sales reaching $70.1 million, a 46.8% increase from $47.8 million in the same quarter of the previous year [2] - Despite the sales growth, pre-tax earnings decreased by 12.2% to $3.5 million, and net earnings fell to $2.4 million compared to $3.0 million in the prior year quarter [2] - The company’s order backlog was $192.9 million as of October 31, 2025, showing an increase from $184.4 million a year earlier, but a decrease from $214.6 million as of April 30, 2025 [3] Domestic Segment - Domestic sales increased by 51.7% to $55.2 million from $36.4 million in the prior year quarter [4] - Net earnings for the domestic segment were $3.6 million, down from $4.5 million in the previous year [4] - EBITDA for the domestic segment was $6.7 million, slightly down from $6.8 million in the prior year quarter, impacted by lower manufacturing volumes in laboratory construction [4] International Segment - International sales rose by 31.0% to $14.9 million from $11.4 million in the prior year quarter [5] - Net earnings for the international segment increased to $641,000 from $356,000 in the previous year [5] - EBITDA for the international segment improved to $860,000 from $592,000 in the prior year quarter, driven by the delivery of large projects booked in prior periods [5] Corporate Segment - The corporate segment reported a pre-tax net loss of $2.5 million, compared to a loss of $2.4 million in the prior year [6] - Corporate segment EBITDA improved to ($1.8 million) from ($2.5 million) in the previous year, aided by the exclusion of prior year costs related to the acquisition of Nu Aire, Inc. [6] - Ongoing strategic investments in the corporate platform are aimed at supporting future growth [6] Financial Position - Total cash on hand was $13.7 million as of October 31, 2025, down from $17.2 million on April 30, 2025 [7] - Working capital increased to $67.8 million from $60.0 million a year earlier [7] - Short-term debt was $4.9 million, and long-term debt decreased to $58.2 million from $60.7 million on April 30, 2025 [8] Management Commentary - The CEO noted expected volatility in project delivery timelines but expressed confidence in strong quoting and booking activity, reflected in the robust backlog, particularly in the domestic segment [9][10] - The acquisition of Nu Aire is seen as a strategic move to diversify and enhance the company's laboratory solutions offerings [10]